Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Amylin Phase III exenatide data

AMLN and partner Eli Lilly (LLY) said exenatide synthetic exendin-4 met the primary endpoint of a reduction in glucose levels

Read the full 207 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE